TY  - CONF
AU  - Kojić, Snežana
AU  - Bošković, Srđan
AU  - Milovanović, Mina
AU  - Stainie, Didier
AU  - Juez, Rubén Marín
AU  - Jasnić, Jovana
AU  - Novković, Mirjana
AU  - Milošević, Emilija
PY  - 2024
UR  - https://www.izfs.org/education/10sczi
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2309
AB  - In contrast to humans, zebrafish have a remarkable ability to regenerate their hearts after injury, while both humans and zebrafish efficiently repair the wounded skeletal muscle. Common players in these two processes might represent potential targets for the development of efficient therapies to stimulate human heart to regenerate after injury. We identified ankrd1a expression to be upregulated in both regenerating zebrafish hearts and in repairing skeletal muscle. Its mammalian homolog ANKRD1/CARP encodes a stress responsive cardiac ankyrin repeat protein involved in transcriptional regulation, sarcomere assembly and mechanosensing. Using a TgBAC(ankrd1a:EGFP) line, we showed that activation of ankrd1a in cryoinjured heart is restricted to border zone cardiomyocytes, implicating this gene in dedifferentiation and proliferation of regenerating cardiomyocytes. After stab wound injury of skeletal muscle expression of the fluorescent reporter was observed from 3 dpi, when new EGFP-positive muscle cells emerged inside the injury zone. At later time points, EGFP-positive myofibers were visible in the deeper tissue layers, concomitant with active repair of the injured tissue. In cryoinjured skeletal muscle, strong activation of ankrd1a was also observed in myofibers adjacent to the injury, and in those on uninjured side. Detection of the transgene in both newly formed myofibers that invade the wound and in the apparently uninjured tissue surrounding the injury suggests the role of ankrd1a in skeletal muscle tissue repair and adaptive processes in uninjured myofibers surrounding the injury site. Our results implicate ankrd1a in zebrafish muscle regeneration, repair and remodeling, promoting it as an attractive target for translational studies, as a player in muscle healing and as a sensor of stressed muscle.
PB  - Society for Zebrafish Research
C3  - 10th Strategic Conference of Zebrafish Investigators
T1  - Zebrafish ankrd1a as a common player  in heart regeneration and skeletal muscle repair
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2309
ER  - 

@conference{
author = "Kojić, Snežana and Bošković, Srđan and Milovanović, Mina and Stainie, Didier and Juez, Rubén Marín and Jasnić, Jovana and Novković, Mirjana and Milošević, Emilija",
year = "2024",
abstract = "In contrast to humans, zebrafish have a remarkable ability to regenerate their hearts after injury, while both humans and zebrafish efficiently repair the wounded skeletal muscle. Common players in these two processes might represent potential targets for the development of efficient therapies to stimulate human heart to regenerate after injury. We identified ankrd1a expression to be upregulated in both regenerating zebrafish hearts and in repairing skeletal muscle. Its mammalian homolog ANKRD1/CARP encodes a stress responsive cardiac ankyrin repeat protein involved in transcriptional regulation, sarcomere assembly and mechanosensing. Using a TgBAC(ankrd1a:EGFP) line, we showed that activation of ankrd1a in cryoinjured heart is restricted to border zone cardiomyocytes, implicating this gene in dedifferentiation and proliferation of regenerating cardiomyocytes. After stab wound injury of skeletal muscle expression of the fluorescent reporter was observed from 3 dpi, when new EGFP-positive muscle cells emerged inside the injury zone. At later time points, EGFP-positive myofibers were visible in the deeper tissue layers, concomitant with active repair of the injured tissue. In cryoinjured skeletal muscle, strong activation of ankrd1a was also observed in myofibers adjacent to the injury, and in those on uninjured side. Detection of the transgene in both newly formed myofibers that invade the wound and in the apparently uninjured tissue surrounding the injury suggests the role of ankrd1a in skeletal muscle tissue repair and adaptive processes in uninjured myofibers surrounding the injury site. Our results implicate ankrd1a in zebrafish muscle regeneration, repair and remodeling, promoting it as an attractive target for translational studies, as a player in muscle healing and as a sensor of stressed muscle.",
publisher = "Society for Zebrafish Research",
journal = "10th Strategic Conference of Zebrafish Investigators",
title = "Zebrafish ankrd1a as a common player  in heart regeneration and skeletal muscle repair",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2309"
}

Kojić, S., Bošković, S., Milovanović, M., Stainie, D., Juez, R. M., Jasnić, J., Novković, M.,& Milošević, E.. (2024). Zebrafish ankrd1a as a common player  in heart regeneration and skeletal muscle repair. in 10th Strategic Conference of Zebrafish Investigators
Society for Zebrafish Research..
https://hdl.handle.net/21.15107/rcub_imagine_2309

Kojić S, Bošković S, Milovanović M, Stainie D, Juez RM, Jasnić J, Novković M, Milošević E. Zebrafish ankrd1a as a common player  in heart regeneration and skeletal muscle repair. in 10th Strategic Conference of Zebrafish Investigators. 2024;.
https://hdl.handle.net/21.15107/rcub_imagine_2309 .

Kojić, Snežana, Bošković, Srđan, Milovanović, Mina, Stainie, Didier, Juez, Rubén Marín, Jasnić, Jovana, Novković, Mirjana, Milošević, Emilija, "Zebrafish ankrd1a as a common player  in heart regeneration and skeletal muscle repair" in 10th Strategic Conference of Zebrafish Investigators (2024),
https://hdl.handle.net/21.15107/rcub_imagine_2309 .

TY  - JOUR
AU  - Novković, Mirjana
AU  - Banović Đeri, Bojana
AU  - RistivojeviĆ, Bojan
AU  - Knežević, Aleksandra
AU  - Janković, Marko
AU  - Tanasić, Vanja
AU  - Radojičić, Verica
AU  - Keckarević, Dusan
AU  - Vidanović, Dejan
AU  - Tešović, Bojana
AU  - Skakić, Anita
AU  - Tolinački, Maja
AU  - Morić, Ivana
AU  - Đorđević, Valentina
PY  - 2024
UR  - https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2024.1332276
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2327
AB  - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the COVID-19 pandemic, has been evolving rapidly causing emergence of new variants and health uncertainties. Monitoring the evolution of the virus was of the utmost importance for public health interventions and the development of national and global mitigation strategies. Here, we report national data on the emergence of new variants, their distribution, and dynamics in a 3-year study conducted from March 2020 to the end of January 2023 in the Republic of Serbia. Nasopharyngeal and oropharyngeal swabs from 2,398 COVID-19-positive patients were collected and sequenced using three different next generation technologies: Oxford Nanopore, Ion Torrent, and DNBSeq. In the subset of 2,107 SARS-CoV-2 sequences which met the quality requirements, detection of mutations, assignment to SARS-CoV-2 lineages, and phylogenetic analysis were performed. During the 3-year period, we detected three variants of concern, namely, Alpha (5.6%), Delta (7.4%), and Omicron (70.3%) and one variant of interest—Omicron recombinant “Kraken” (XBB1.5) (<1%), whereas 16.8% of the samples belonged to other SARS-CoV-2 (sub)lineages. The detected SARS-CoV-2 (sub)lineages resulted in eight COVID-19 pandemic waves in Serbia, which correspond to the pandemic waves reported in Europe and the United States. Wave dynamics in Serbia showed the most resemblance with the profile of pandemic waves in southern Europe, consistent with the southeastern European location of Serbia. The samples were assigned to sixteen SARS-CoV-2 Nextstrain clades: 20A, 20B, 20C, 20D, 20E, 20G, 20I, 21J, 21K, 21L, 22A, 22B, 22C, 22D, 22E, and 22F and six different Omicron recombinants (XZ, XAZ, XAS, XBB, XBF, and XBK). The 10 most common mutations detected in the coding and untranslated regions of the SARS-CoV-2 genomes included four mutations affecting the spike protein (S:D614G, S:T478K, S:P681H, and S:S477N) and one mutation at each of the following positions: 5′-untranslated region (5’UTR:241); N protein (N:RG203KR); NSP3 protein (NSP3:F106F); NSP4 protein (NSP4:T492I); NSP6 protein (NSP6: S106/G107/F108 - triple deletion), and NSP12b protein (NSP12b:P314L). This national-level study is the most comprehensive in terms of sequencing and genomic surveillance of SARS-CoV-2 during the pandemic in Serbia, highlighting the importance of establishing and maintaining good national practice for monitoring SARS-CoV-2 and other viruses circulating worldwide.
AB  - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the COVID-19 pandemic, has been evolving rapidly causing emergence of new variants and health uncertainties. Monitoring the evolution of the virus was of the utmost importance for public health interventions and the development of national and global mitigation strategies. Here, we report national data on the emergence of new variants, their distribution, and dynamics in a 3-year study conducted from March 2020 to the end of January 2023 in the Republic of Serbia. Nasopharyngeal and oropharyngeal swabs from 2,398 COVID-19- positive patients were collected and sequenced using three different next generation technologies: Oxford Nanopore, Ion Torrent, and DNBSeq. In the subset of 2,107 SARS-CoV-2 sequences which met the quality requirements, detection of mutations, assignment to SARS-CoV-2 lineages, and phylogenetic analysis were performed. During the 3-year period, we detected three variants of concern, namely, Alpha (5.6%), Delta (7.4%), and Omicron (70.3%) and one variant of interest—Omicron recombinant “Kraken” (XBB1.5) (<1%), whereas 16.8% of the samples belonged to other SARS-CoV-2 (sub)lineages. The detected SARS-CoV-2 (sub)lineages resulted in eight COVID-19 pandemic waves in Serbia, which correspond to the pandemic waves reported in Europe and the United States. Wave dynamics in Serbia showed the most resemblance with the profile of pandemic waves in southern Europe, consistent with the southeastern European location of Serbia. The samples were assigned to sixteen SARS-CoV-2 Nextstrain clades: 20A, 20B, 20C, 20D, 20E, 20G, 20I, 21J, 21K, 21L, 22A, 22B, 22C, 22D, 22E, and 22F and six different Omicron recombinants (XZ, XAZ, XAS, XBB, XBF, and XBK). The 10 most common mutations detected in the coding and untranslated regions of the SARS-CoV-2 genomes included four mutations affecting the spike protein (S:D614G, S:T478K, S:P681H, and S:S477N) and one mutation at each of the following positions: 5′-untranslated region (5’UTR:241); N protein (N:RG203KR); NSP3 protein (NSP3:F106F); NSP4 protein (NSP4:T492I); NSP6 protein (NSP6: S106/G107/F108 - triple deletion), and NSP12b protein (NSP12b:P314L). This national-level study is the most comprehensive in terms of sequencing and genomic surveillance of SARS-CoV-2 during the pandemic in Serbia, highlighting the importance of establishing and maintaining good national practice for monitoring SARS-CoV-2 and other viruses circulating worldwide.
PB  - Frontiers
T2  - Frontiers in Microbiology
T2  - Frontiers in Microbiology
T1  - Genome sequence diversity of SARS-CoV-2 in Serbia: insights gained from a 3-year pandemic study
VL  - 15
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2327
ER  - 

@article{
author = "Novković, Mirjana and Banović Đeri, Bojana and RistivojeviĆ, Bojan and Knežević, Aleksandra and Janković, Marko and Tanasić, Vanja and Radojičić, Verica and Keckarević, Dusan and Vidanović, Dejan and Tešović, Bojana and Skakić, Anita and Tolinački, Maja and Morić, Ivana and Đorđević, Valentina",
year = "2024",
abstract = "The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the COVID-19 pandemic, has been evolving rapidly causing emergence of new variants and health uncertainties. Monitoring the evolution of the virus was of the utmost importance for public health interventions and the development of national and global mitigation strategies. Here, we report national data on the emergence of new variants, their distribution, and dynamics in a 3-year study conducted from March 2020 to the end of January 2023 in the Republic of Serbia. Nasopharyngeal and oropharyngeal swabs from 2,398 COVID-19-positive patients were collected and sequenced using three different next generation technologies: Oxford Nanopore, Ion Torrent, and DNBSeq. In the subset of 2,107 SARS-CoV-2 sequences which met the quality requirements, detection of mutations, assignment to SARS-CoV-2 lineages, and phylogenetic analysis were performed. During the 3-year period, we detected three variants of concern, namely, Alpha (5.6%), Delta (7.4%), and Omicron (70.3%) and one variant of interest—Omicron recombinant “Kraken” (XBB1.5) (<1%), whereas 16.8% of the samples belonged to other SARS-CoV-2 (sub)lineages. The detected SARS-CoV-2 (sub)lineages resulted in eight COVID-19 pandemic waves in Serbia, which correspond to the pandemic waves reported in Europe and the United States. Wave dynamics in Serbia showed the most resemblance with the profile of pandemic waves in southern Europe, consistent with the southeastern European location of Serbia. The samples were assigned to sixteen SARS-CoV-2 Nextstrain clades: 20A, 20B, 20C, 20D, 20E, 20G, 20I, 21J, 21K, 21L, 22A, 22B, 22C, 22D, 22E, and 22F and six different Omicron recombinants (XZ, XAZ, XAS, XBB, XBF, and XBK). The 10 most common mutations detected in the coding and untranslated regions of the SARS-CoV-2 genomes included four mutations affecting the spike protein (S:D614G, S:T478K, S:P681H, and S:S477N) and one mutation at each of the following positions: 5′-untranslated region (5’UTR:241); N protein (N:RG203KR); NSP3 protein (NSP3:F106F); NSP4 protein (NSP4:T492I); NSP6 protein (NSP6: S106/G107/F108 - triple deletion), and NSP12b protein (NSP12b:P314L). This national-level study is the most comprehensive in terms of sequencing and genomic surveillance of SARS-CoV-2 during the pandemic in Serbia, highlighting the importance of establishing and maintaining good national practice for monitoring SARS-CoV-2 and other viruses circulating worldwide., The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the COVID-19 pandemic, has been evolving rapidly causing emergence of new variants and health uncertainties. Monitoring the evolution of the virus was of the utmost importance for public health interventions and the development of national and global mitigation strategies. Here, we report national data on the emergence of new variants, their distribution, and dynamics in a 3-year study conducted from March 2020 to the end of January 2023 in the Republic of Serbia. Nasopharyngeal and oropharyngeal swabs from 2,398 COVID-19- positive patients were collected and sequenced using three different next generation technologies: Oxford Nanopore, Ion Torrent, and DNBSeq. In the subset of 2,107 SARS-CoV-2 sequences which met the quality requirements, detection of mutations, assignment to SARS-CoV-2 lineages, and phylogenetic analysis were performed. During the 3-year period, we detected three variants of concern, namely, Alpha (5.6%), Delta (7.4%), and Omicron (70.3%) and one variant of interest—Omicron recombinant “Kraken” (XBB1.5) (<1%), whereas 16.8% of the samples belonged to other SARS-CoV-2 (sub)lineages. The detected SARS-CoV-2 (sub)lineages resulted in eight COVID-19 pandemic waves in Serbia, which correspond to the pandemic waves reported in Europe and the United States. Wave dynamics in Serbia showed the most resemblance with the profile of pandemic waves in southern Europe, consistent with the southeastern European location of Serbia. The samples were assigned to sixteen SARS-CoV-2 Nextstrain clades: 20A, 20B, 20C, 20D, 20E, 20G, 20I, 21J, 21K, 21L, 22A, 22B, 22C, 22D, 22E, and 22F and six different Omicron recombinants (XZ, XAZ, XAS, XBB, XBF, and XBK). The 10 most common mutations detected in the coding and untranslated regions of the SARS-CoV-2 genomes included four mutations affecting the spike protein (S:D614G, S:T478K, S:P681H, and S:S477N) and one mutation at each of the following positions: 5′-untranslated region (5’UTR:241); N protein (N:RG203KR); NSP3 protein (NSP3:F106F); NSP4 protein (NSP4:T492I); NSP6 protein (NSP6: S106/G107/F108 - triple deletion), and NSP12b protein (NSP12b:P314L). This national-level study is the most comprehensive in terms of sequencing and genomic surveillance of SARS-CoV-2 during the pandemic in Serbia, highlighting the importance of establishing and maintaining good national practice for monitoring SARS-CoV-2 and other viruses circulating worldwide.",
publisher = "Frontiers",
journal = "Frontiers in Microbiology, Frontiers in Microbiology",
title = "Genome sequence diversity of SARS-CoV-2 in Serbia: insights gained from a 3-year pandemic study",
volume = "15",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2327"
}

Novković, M., Banović Đeri, B., RistivojeviĆ, B., Knežević, A., Janković, M., Tanasić, V., Radojičić, V., Keckarević, D., Vidanović, D., Tešović, B., Skakić, A., Tolinački, M., Morić, I.,& Đorđević, V.. (2024). Genome sequence diversity of SARS-CoV-2 in Serbia: insights gained from a 3-year pandemic study. in Frontiers in Microbiology
Frontiers., 15.
https://hdl.handle.net/21.15107/rcub_imagine_2327

Novković M, Banović Đeri B, RistivojeviĆ B, Knežević A, Janković M, Tanasić V, Radojičić V, Keckarević D, Vidanović D, Tešović B, Skakić A, Tolinački M, Morić I, Đorđević V. Genome sequence diversity of SARS-CoV-2 in Serbia: insights gained from a 3-year pandemic study. in Frontiers in Microbiology. 2024;15.
https://hdl.handle.net/21.15107/rcub_imagine_2327 .

Novković, Mirjana, Banović Đeri, Bojana, RistivojeviĆ, Bojan, Knežević, Aleksandra, Janković, Marko, Tanasić, Vanja, Radojičić, Verica, Keckarević, Dusan, Vidanović, Dejan, Tešović, Bojana, Skakić, Anita, Tolinački, Maja, Morić, Ivana, Đorđević, Valentina, "Genome sequence diversity of SARS-CoV-2 in Serbia: insights gained from a 3-year pandemic study" in Frontiers in Microbiology, 15 (2024),
https://hdl.handle.net/21.15107/rcub_imagine_2327 .

TY  - JOUR
AU  - Milošević, Emilija
AU  - Novković, Mirjana
AU  - Cenni, Vittoria
AU  - Bavelloni, Alberto
AU  - Kojić, Snežana
AU  - Jasnić, Jovana
PY  - 2024
UR  - https://doi.org/10.1007/s00418-024-02272-2
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2325
AB  - Rhabdomyosarcoma (RMS) is the most common soft tissue malignancy in children and adolescents. Respecting the age of the patients and the tumor aggressiveness, investigation of the molecular mechanisms of RMS tumorigenesis is directed toward the identification of novel therapeutic targets. To contribute to a better understanding of the molecular pathology of RMS, we investigated ankyrin repeat domain 1 (ANKRD1), designated as a potential marker for differential diagnostics. In this study, we used three RMS cell lines (SJRH30, RD, and HS-729) to assess its expression profile, intracellular localization, and turnover. They express wild-type ANKRD1, as judged by the sequencing of the open reading frame. Each cell line expressed a different amount of ANKRD1 protein, although the transcript level was similar. According to western blot analysis, ANKRD1 protein was expressed at detectable levels in the SJRH30 and RD cells (SJRH30 > RD), but not in the HS-729, even after immunoprecipitation. Immunocytochemistry revealed nuclear and cytoplasmic localization of ANKRD1 in all examined cell lines. Moreover, the punctate pattern of ANKRD1 staining in the nuclei of RD and HS-729 cells overlapped with coilin, indicating its association with Cajal bodies. We have shown that RMS cells are not able to overexpress ANKRD1 protein, which can be attributed to its proteasomal degradation. The unsuccessful attempt to overexpress ANKRD1 in RMS cells indicates the possibility that its overexpression may have detrimental effects for RMS cells and opens a window for further research into its role in RMS pathogenesis and for potential therapeutic targeting.
PB  - Springer Nature
T2  - Histochemistry and Cell Biology
T2  - Histochemistry and Cell BiologyHistochem Cell Biol
T1  - Molecular characterization of ANKRD1 in rhabdomyosarcoma cell lines: expression, localization, and proteasomal degradation
DO  - 10.1007/s00418-024-02272-2
ER  - 

@article{
author = "Milošević, Emilija and Novković, Mirjana and Cenni, Vittoria and Bavelloni, Alberto and Kojić, Snežana and Jasnić, Jovana",
year = "2024",
abstract = "Rhabdomyosarcoma (RMS) is the most common soft tissue malignancy in children and adolescents. Respecting the age of the patients and the tumor aggressiveness, investigation of the molecular mechanisms of RMS tumorigenesis is directed toward the identification of novel therapeutic targets. To contribute to a better understanding of the molecular pathology of RMS, we investigated ankyrin repeat domain 1 (ANKRD1), designated as a potential marker for differential diagnostics. In this study, we used three RMS cell lines (SJRH30, RD, and HS-729) to assess its expression profile, intracellular localization, and turnover. They express wild-type ANKRD1, as judged by the sequencing of the open reading frame. Each cell line expressed a different amount of ANKRD1 protein, although the transcript level was similar. According to western blot analysis, ANKRD1 protein was expressed at detectable levels in the SJRH30 and RD cells (SJRH30 > RD), but not in the HS-729, even after immunoprecipitation. Immunocytochemistry revealed nuclear and cytoplasmic localization of ANKRD1 in all examined cell lines. Moreover, the punctate pattern of ANKRD1 staining in the nuclei of RD and HS-729 cells overlapped with coilin, indicating its association with Cajal bodies. We have shown that RMS cells are not able to overexpress ANKRD1 protein, which can be attributed to its proteasomal degradation. The unsuccessful attempt to overexpress ANKRD1 in RMS cells indicates the possibility that its overexpression may have detrimental effects for RMS cells and opens a window for further research into its role in RMS pathogenesis and for potential therapeutic targeting.",
publisher = "Springer Nature",
journal = "Histochemistry and Cell Biology, Histochemistry and Cell BiologyHistochem Cell Biol",
title = "Molecular characterization of ANKRD1 in rhabdomyosarcoma cell lines: expression, localization, and proteasomal degradation",
doi = "10.1007/s00418-024-02272-2"
}

Milošević, E., Novković, M., Cenni, V., Bavelloni, A., Kojić, S.,& Jasnić, J.. (2024). Molecular characterization of ANKRD1 in rhabdomyosarcoma cell lines: expression, localization, and proteasomal degradation. in Histochemistry and Cell Biology
Springer Nature..
https://doi.org/10.1007/s00418-024-02272-2

Milošević E, Novković M, Cenni V, Bavelloni A, Kojić S, Jasnić J. Molecular characterization of ANKRD1 in rhabdomyosarcoma cell lines: expression, localization, and proteasomal degradation. in Histochemistry and Cell Biology. 2024;.
doi:10.1007/s00418-024-02272-2 .

Milošević, Emilija, Novković, Mirjana, Cenni, Vittoria, Bavelloni, Alberto, Kojić, Snežana, Jasnić, Jovana, "Molecular characterization of ANKRD1 in rhabdomyosarcoma cell lines: expression, localization, and proteasomal degradation" in Histochemistry and Cell Biology (2024),
https://doi.org/10.1007/s00418-024-02272-2 . .

TY  - CONF
AU  - Milovanović, Mina
AU  - Bošković, Srđan
AU  - Jasnić, Jovana
AU  - Novković, Mirjana
AU  - Milošević, Emilija
AU  - Kojić, Snežana
PY  - 2023
UR  - https://zebrafish2023.org/
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2023
AB  - In our previous work, using transgenic zebrafish line TgBAC(ankrd1a:EGFP), we showed activation
of the zebrafish ankrd1a gene in border zone cardiomyocytes of cryoinjured heart and in close
proximity of needle-stab wounds in skeletal muscle, indicating its involvement in muscle
regeneration. Our results implicated ankrd1a in zebrafish skeletal muscle tissue repair and
remodeling, as a sensor of stressed muscle. Here we take a closer look at the spatio-temporal
expression profile of the ankrd1a gene in injured zebrafish skeletal muscle by analyzing cryosections
prepared from wounded tissue of TgBAC(ankrd1a:EGFP) adults at 1, 3, 5, 7 and 10 days post-injury
(dpi). The expression of the fluorescent reporter was observed from 3 dpi and remained until 10 dpi.
At 3dpi, new GFP-positive muscle cells emerged inside the injury zone, at the site of needle entry,
while in the later days (5, 7 and 10 dpi), newly formed GFP-positive myofibers were visible in the
deeper tissue layers within the injury, indicating active repair of the injured tissue. To identify cells
in which ankrd1a is activated after injury, we stained the sections for markers of satellite-like cells,
undifferentiated and differentiated muscle cells, and mature myofibers. Since the reporter was
detected both in the newly formed myofibers that invade the wound and in the apparently uninjured
tissue surrounding the injury, we hypothesize that ankrd1a is not only involved in satellite celldependent tissue repair, but its expression might be a hallmark of adaptive process in undamaged
myofibers surrounding the physical injury.
C3  - 12th European Zebrafish Meeting
T1  - Expression profile of ankrd1a during repair of injured zebrafish skeletal muscle
EP  - 276
SP  - 276
SP  - 0254
VL  - 14
VL  - 12
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2023
ER  - 

@conference{
author = "Milovanović, Mina and Bošković, Srđan and Jasnić, Jovana and Novković, Mirjana and Milošević, Emilija and Kojić, Snežana",
year = "2023",
abstract = "In our previous work, using transgenic zebrafish line TgBAC(ankrd1a:EGFP), we showed activation
of the zebrafish ankrd1a gene in border zone cardiomyocytes of cryoinjured heart and in close
proximity of needle-stab wounds in skeletal muscle, indicating its involvement in muscle
regeneration. Our results implicated ankrd1a in zebrafish skeletal muscle tissue repair and
remodeling, as a sensor of stressed muscle. Here we take a closer look at the spatio-temporal
expression profile of the ankrd1a gene in injured zebrafish skeletal muscle by analyzing cryosections
prepared from wounded tissue of TgBAC(ankrd1a:EGFP) adults at 1, 3, 5, 7 and 10 days post-injury
(dpi). The expression of the fluorescent reporter was observed from 3 dpi and remained until 10 dpi.
At 3dpi, new GFP-positive muscle cells emerged inside the injury zone, at the site of needle entry,
while in the later days (5, 7 and 10 dpi), newly formed GFP-positive myofibers were visible in the
deeper tissue layers within the injury, indicating active repair of the injured tissue. To identify cells
in which ankrd1a is activated after injury, we stained the sections for markers of satellite-like cells,
undifferentiated and differentiated muscle cells, and mature myofibers. Since the reporter was
detected both in the newly formed myofibers that invade the wound and in the apparently uninjured
tissue surrounding the injury, we hypothesize that ankrd1a is not only involved in satellite celldependent tissue repair, but its expression might be a hallmark of adaptive process in undamaged
myofibers surrounding the physical injury.",
journal = "12th European Zebrafish Meeting",
title = "Expression profile of ankrd1a during repair of injured zebrafish skeletal muscle",
pages = "276-276-0254",
volume = "14, 12",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2023"
}

Milovanović, M., Bošković, S., Jasnić, J., Novković, M., Milošević, E.,& Kojić, S.. (2023). Expression profile of ankrd1a during repair of injured zebrafish skeletal muscle. in 12th European Zebrafish Meeting, 14, 276-276.
https://hdl.handle.net/21.15107/rcub_imagine_2023

Milovanović M, Bošković S, Jasnić J, Novković M, Milošević E, Kojić S. Expression profile of ankrd1a during repair of injured zebrafish skeletal muscle. in 12th European Zebrafish Meeting. 2023;14:276-276.
https://hdl.handle.net/21.15107/rcub_imagine_2023 .

Milovanović, Mina, Bošković, Srđan, Jasnić, Jovana, Novković, Mirjana, Milošević, Emilija, Kojić, Snežana, "Expression profile of ankrd1a during repair of injured zebrafish skeletal muscle" in 12th European Zebrafish Meeting, 14 (2023):276-276,
https://hdl.handle.net/21.15107/rcub_imagine_2023 .

TY  - JOUR
AU  - Milošević, Emilija
AU  - Stanisavljević, Nemanja
AU  - Bošković, Srđan
AU  - Stamenković, Nemanja
AU  - Novković, Mirjana
AU  - Bavelloni, Alberto
AU  - Cenni, Vittoria
AU  - Kojić, Snežana
AU  - Jasnić, Jovana
PY  - 2023
UR  - https://doi.org/10.1007/s00432-023-04930-9
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1928
AB  - Sarcomas are rare and heterogenic tumors with unclear etiology. They develop in bone and connective tissue, mainly in pediatric patients. To increase efficacy of current therapeutic options, natural products showing selective toxicity to tumor cells are extensively investigated. Here, we evaluated antitumor activity of bacterial pigment violacein in osteosarcoma (OS) and rhabdomyosarcoma (RMS) cell lines.
PB  - Springer Nature
T2  - Journal of Cancer Research and Clinical Oncology
T1  - Antitumor activity of natural pigment violacein against osteosarcoma and rhabdomyosarcoma cell lines
DO  - 10.1007/s00432-023-04930-9
ER  - 

@article{
author = "Milošević, Emilija and Stanisavljević, Nemanja and Bošković, Srđan and Stamenković, Nemanja and Novković, Mirjana and Bavelloni, Alberto and Cenni, Vittoria and Kojić, Snežana and Jasnić, Jovana",
year = "2023",
abstract = "Sarcomas are rare and heterogenic tumors with unclear etiology. They develop in bone and connective tissue, mainly in pediatric patients. To increase efficacy of current therapeutic options, natural products showing selective toxicity to tumor cells are extensively investigated. Here, we evaluated antitumor activity of bacterial pigment violacein in osteosarcoma (OS) and rhabdomyosarcoma (RMS) cell lines.",
publisher = "Springer Nature",
journal = "Journal of Cancer Research and Clinical Oncology",
title = "Antitumor activity of natural pigment violacein against osteosarcoma and rhabdomyosarcoma cell lines",
doi = "10.1007/s00432-023-04930-9"
}

Milošević, E., Stanisavljević, N., Bošković, S., Stamenković, N., Novković, M., Bavelloni, A., Cenni, V., Kojić, S.,& Jasnić, J.. (2023). Antitumor activity of natural pigment violacein against osteosarcoma and rhabdomyosarcoma cell lines. in Journal of Cancer Research and Clinical Oncology
Springer Nature..
https://doi.org/10.1007/s00432-023-04930-9

Milošević E, Stanisavljević N, Bošković S, Stamenković N, Novković M, Bavelloni A, Cenni V, Kojić S, Jasnić J. Antitumor activity of natural pigment violacein against osteosarcoma and rhabdomyosarcoma cell lines. in Journal of Cancer Research and Clinical Oncology. 2023;.
doi:10.1007/s00432-023-04930-9 .

Milošević, Emilija, Stanisavljević, Nemanja, Bošković, Srđan, Stamenković, Nemanja, Novković, Mirjana, Bavelloni, Alberto, Cenni, Vittoria, Kojić, Snežana, Jasnić, Jovana, "Antitumor activity of natural pigment violacein against osteosarcoma and rhabdomyosarcoma cell lines" in Journal of Cancer Research and Clinical Oncology (2023),
https://doi.org/10.1007/s00432-023-04930-9 . .

TY  - CONF
AU  - Milovanović, Mina
AU  - Bošković, Srđan
AU  - Jasnić, Jovana
AU  - Novković, Mirjana
AU  - Milošević, Emilija
AU  - Kojić, Snežana
PY  - 2023
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2132
AB  - Introduction: In contrast to humans, zebrafish have a remarkable ability to regenerate injured heart
through a complex and highly orchestrated processinvolving all cardiac structures. The majorsource of
new myocardial cells are resident cardiomyocytes, which dedifferentiate and reinitiate proliferation, invading the area of injury to replace the lost myocardium. The response of the myocardium and coronary
vasculature is preceded by activation of epi- and endocardium, which form active scaffolds to guide regeneration. The aim of thisstudy wasto identify cardiac structuresin which ankrd1a gene is activated during zebrafish heart regeneration.
Methods: We crossed several zebrafish reporter lines: TgBAC(ankrd1a:EGFP) (to identify cells expressing
ankrd1a), Tg(myl7:nls-dsRedExpress) (for labeling cardiomyocyte nuclei) and Tg(kdrl:RAS-mCherry) (for labeling endocardial/endothelial cells). Zebrafish hearts were cryoinjured and left to regenerate for 3 and
7 days. Dedifferentiating cardiomyocytes and epicardial cells were immunostained with anti-MYH7 and
anti-caveolin1 antibody, respectively. Cells labeled with transgenes and immunostaining were visualized on tissue cryosections by fluorescent microscopy.
Results: Zebrafish ankrd1a was activated in the injury border zone cardiomyocytes, located between
the injured and remote myocardium. Its expression preceded that of a dedifferentiation marker, MYH7.
The TgBAC(ankrd1a:EGFP) transgene was not detected in epicardial or endocardial cells of regenerating
zebrafish heart.
Conclusion: Activation of ankrd1a during regeneration of zebrafish heart is restricted to borderzone
cardiomyocytes, implicating this gene in dedifferentiation and proliferation of cardiomyocytes. The absence of ankrd1a expression in epicardium and endocardium indicatesthat this gene does not contribute
to the regeneration process occuring in these layers of the heart.
PB  - Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade
C3  - CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia
T1  - Spatial profile of ankrd1a activation during regeneration of zebrafish heart
EP  - 141
SP  - 141
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2132
ER  - 

@conference{
author = "Milovanović, Mina and Bošković, Srđan and Jasnić, Jovana and Novković, Mirjana and Milošević, Emilija and Kojić, Snežana",
year = "2023",
abstract = "Introduction: In contrast to humans, zebrafish have a remarkable ability to regenerate injured heart
through a complex and highly orchestrated processinvolving all cardiac structures. The majorsource of
new myocardial cells are resident cardiomyocytes, which dedifferentiate and reinitiate proliferation, invading the area of injury to replace the lost myocardium. The response of the myocardium and coronary
vasculature is preceded by activation of epi- and endocardium, which form active scaffolds to guide regeneration. The aim of thisstudy wasto identify cardiac structuresin which ankrd1a gene is activated during zebrafish heart regeneration.
Methods: We crossed several zebrafish reporter lines: TgBAC(ankrd1a:EGFP) (to identify cells expressing
ankrd1a), Tg(myl7:nls-dsRedExpress) (for labeling cardiomyocyte nuclei) and Tg(kdrl:RAS-mCherry) (for labeling endocardial/endothelial cells). Zebrafish hearts were cryoinjured and left to regenerate for 3 and
7 days. Dedifferentiating cardiomyocytes and epicardial cells were immunostained with anti-MYH7 and
anti-caveolin1 antibody, respectively. Cells labeled with transgenes and immunostaining were visualized on tissue cryosections by fluorescent microscopy.
Results: Zebrafish ankrd1a was activated in the injury border zone cardiomyocytes, located between
the injured and remote myocardium. Its expression preceded that of a dedifferentiation marker, MYH7.
The TgBAC(ankrd1a:EGFP) transgene was not detected in epicardial or endocardial cells of regenerating
zebrafish heart.
Conclusion: Activation of ankrd1a during regeneration of zebrafish heart is restricted to borderzone
cardiomyocytes, implicating this gene in dedifferentiation and proliferation of cardiomyocytes. The absence of ankrd1a expression in epicardium and endocardium indicatesthat this gene does not contribute
to the regeneration process occuring in these layers of the heart.",
publisher = "Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade",
journal = "CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia",
title = "Spatial profile of ankrd1a activation during regeneration of zebrafish heart",
pages = "141-141",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2132"
}

Milovanović, M., Bošković, S., Jasnić, J., Novković, M., Milošević, E.,& Kojić, S.. (2023). Spatial profile of ankrd1a activation during regeneration of zebrafish heart. in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia
Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade., 141-141.
https://hdl.handle.net/21.15107/rcub_imagine_2132

Milovanović M, Bošković S, Jasnić J, Novković M, Milošević E, Kojić S. Spatial profile of ankrd1a activation during regeneration of zebrafish heart. in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia. 2023;:141-141.
https://hdl.handle.net/21.15107/rcub_imagine_2132 .

Milovanović, Mina, Bošković, Srđan, Jasnić, Jovana, Novković, Mirjana, Milošević, Emilija, Kojić, Snežana, "Spatial profile of ankrd1a activation during regeneration of zebrafish heart" in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia (2023):141-141,
https://hdl.handle.net/21.15107/rcub_imagine_2132 .

TY  - JOUR
AU  - Milošević, Emilija
AU  - Stanisavljević, Nemanja
AU  - Bošković, Srđan
AU  - Stamenković, Nemanja
AU  - Novković, Mirjana
AU  - Bavelloni, Alberto
AU  - Cenni, Vittoria
AU  - Kojić, Snežana
AU  - Jasnić, Jovana
PY  - 2023
UR  - https://doi.org/10.1007/s00432-023-04930-9
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1918
AB  - Sarcomas are rare and heterogenic tumors with unclear etiology. They develop in bone and connective tissue, mainly in pediatric patients. To increase efficacy of current therapeutic options, natural products showing selective toxicity to tumor cells are extensively investigated. Here, we evaluated antitumor activity of bacterial pigment violacein in osteosarcoma (OS) and rhabdomyosarcoma (RMS) cell lines.
PB  - Springer Nature
T2  - Journal of Cancer Research and Clinical Oncology
T1  - Antitumor activity of natural pigment violacein against osteosarcoma and rhabdomyosarcoma cell lines
DO  - 10.1007/s00432-023-04930-9
ER  - 

@article{
author = "Milošević, Emilija and Stanisavljević, Nemanja and Bošković, Srđan and Stamenković, Nemanja and Novković, Mirjana and Bavelloni, Alberto and Cenni, Vittoria and Kojić, Snežana and Jasnić, Jovana",
year = "2023",
abstract = "Sarcomas are rare and heterogenic tumors with unclear etiology. They develop in bone and connective tissue, mainly in pediatric patients. To increase efficacy of current therapeutic options, natural products showing selective toxicity to tumor cells are extensively investigated. Here, we evaluated antitumor activity of bacterial pigment violacein in osteosarcoma (OS) and rhabdomyosarcoma (RMS) cell lines.",
publisher = "Springer Nature",
journal = "Journal of Cancer Research and Clinical Oncology",
title = "Antitumor activity of natural pigment violacein against osteosarcoma and rhabdomyosarcoma cell lines",
doi = "10.1007/s00432-023-04930-9"
}

Milošević, E., Stanisavljević, N., Bošković, S., Stamenković, N., Novković, M., Bavelloni, A., Cenni, V., Kojić, S.,& Jasnić, J.. (2023). Antitumor activity of natural pigment violacein against osteosarcoma and rhabdomyosarcoma cell lines. in Journal of Cancer Research and Clinical Oncology
Springer Nature..
https://doi.org/10.1007/s00432-023-04930-9

Milošević E, Stanisavljević N, Bošković S, Stamenković N, Novković M, Bavelloni A, Cenni V, Kojić S, Jasnić J. Antitumor activity of natural pigment violacein against osteosarcoma and rhabdomyosarcoma cell lines. in Journal of Cancer Research and Clinical Oncology. 2023;.
doi:10.1007/s00432-023-04930-9 .

Milošević, Emilija, Stanisavljević, Nemanja, Bošković, Srđan, Stamenković, Nemanja, Novković, Mirjana, Bavelloni, Alberto, Cenni, Vittoria, Kojić, Snežana, Jasnić, Jovana, "Antitumor activity of natural pigment violacein against osteosarcoma and rhabdomyosarcoma cell lines" in Journal of Cancer Research and Clinical Oncology (2023),
https://doi.org/10.1007/s00432-023-04930-9 . .

TY  - CONF
AU  - Novković, Mirjana
AU  - Vasić, Marko
AU  - Jasnić, Jovana
AU  - Milošević, Emilija
AU  - Milovanović, Mina
AU  - Savić, Slobodan
AU  - Kojić, Snežana
PY  - 2023
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2114
AB  - Introduction: Ankyrin Repeat Domain 2 (ANKRD2) is expressed in skeletal muscle, where plays a role in
muscle development, differentiation and adaptation to stress. Human skeletal muscle consists of three
major fiber types: type 1 (slow-twitch, oxidative), type 2A (fast-twitch, oxidative) and type 2X (fast-twitch,
glycolytic). ANKRD2 is reported to be primarily expressed in type 1 myofibers. However, recent findings
on human single myofibers and our study of chicken muscles have shown that this protein may also be
expressed in type 2A fibers. Hence, our objective was to examine whether ANKRD2 is present in human
fast, type 2A muscle fibers using immunohistochemistry.
Methods: Samples of large leg musclessoleus, gastrocnemius, vastusintermedius and vastuslateralis were
obtained from human cadaveric tissue. Serial cryosections were independently stained with anti-ANKRD2
and antibodies for different myosin heavy chain isoforms (6H1 for type 2X, BF35 for type 1 and 2A, antiMHCs for type 1 and anti-MHCf for type 2A and 2X fibers). Immunostained tissues were analyzed by fluorescent microscopy.
Results: In addition to slow, type 1, ANKRD2 wasfound expressed in fast, type 2A myofibers, which both
have oxidative metabolism. Further, we did not observe ANDRD2 expression in glycolytic, type 2X
myiofibers. This pattern of ANKRD2 expression was consistent across all examined muscles.
Conclusion: Our resultsimplicate that the regulatory mechanism of ANKRD2 expression in human skeletal muscle is associated with oxidative metabolism, rather than muscle contraction speed.
PB  - Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade
C3  - CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia
T1  - Determination of muscle fiber types expressing ANKRD2
EP  - 155
SP  - 155
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2114
ER  - 

@conference{
author = "Novković, Mirjana and Vasić, Marko and Jasnić, Jovana and Milošević, Emilija and Milovanović, Mina and Savić, Slobodan and Kojić, Snežana",
year = "2023",
abstract = "Introduction: Ankyrin Repeat Domain 2 (ANKRD2) is expressed in skeletal muscle, where plays a role in
muscle development, differentiation and adaptation to stress. Human skeletal muscle consists of three
major fiber types: type 1 (slow-twitch, oxidative), type 2A (fast-twitch, oxidative) and type 2X (fast-twitch,
glycolytic). ANKRD2 is reported to be primarily expressed in type 1 myofibers. However, recent findings
on human single myofibers and our study of chicken muscles have shown that this protein may also be
expressed in type 2A fibers. Hence, our objective was to examine whether ANKRD2 is present in human
fast, type 2A muscle fibers using immunohistochemistry.
Methods: Samples of large leg musclessoleus, gastrocnemius, vastusintermedius and vastuslateralis were
obtained from human cadaveric tissue. Serial cryosections were independently stained with anti-ANKRD2
and antibodies for different myosin heavy chain isoforms (6H1 for type 2X, BF35 for type 1 and 2A, antiMHCs for type 1 and anti-MHCf for type 2A and 2X fibers). Immunostained tissues were analyzed by fluorescent microscopy.
Results: In addition to slow, type 1, ANKRD2 wasfound expressed in fast, type 2A myofibers, which both
have oxidative metabolism. Further, we did not observe ANDRD2 expression in glycolytic, type 2X
myiofibers. This pattern of ANKRD2 expression was consistent across all examined muscles.
Conclusion: Our resultsimplicate that the regulatory mechanism of ANKRD2 expression in human skeletal muscle is associated with oxidative metabolism, rather than muscle contraction speed.",
publisher = "Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade",
journal = "CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia",
title = "Determination of muscle fiber types expressing ANKRD2",
pages = "155-155",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2114"
}

Novković, M., Vasić, M., Jasnić, J., Milošević, E., Milovanović, M., Savić, S.,& Kojić, S.. (2023). Determination of muscle fiber types expressing ANKRD2. in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia
Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade., 155-155.
https://hdl.handle.net/21.15107/rcub_imagine_2114

Novković M, Vasić M, Jasnić J, Milošević E, Milovanović M, Savić S, Kojić S. Determination of muscle fiber types expressing ANKRD2. in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia. 2023;:155-155.
https://hdl.handle.net/21.15107/rcub_imagine_2114 .

Novković, Mirjana, Vasić, Marko, Jasnić, Jovana, Milošević, Emilija, Milovanović, Mina, Savić, Slobodan, Kojić, Snežana, "Determination of muscle fiber types expressing ANKRD2" in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia (2023):155-155,
https://hdl.handle.net/21.15107/rcub_imagine_2114 .

TY  - DATA
AU  - Milošević, Emilija
AU  - Stanisavljević, Nemanja
AU  - Bošković, Srđan
AU  - Stamenković, Nemanja
AU  - Novković, Mirjana
AU  - Bavelloni, Alberto
AU  - Cenni, Vittoria
AU  - Kojić, Snežana
AU  - Jasnić, Jovana
PY  - 2023
UR  - https://doi.org/10.1007/s00432-023-04930-9
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1929
T2  - Journal of Cancer Research and Clinical Oncology
T1  - Supplementary data for the article: Milošević, E., Stanisavljević, N., Bošković, S., Stamenković, N., Novković, M., Bavelloni, A., Cenni, V., Kojić, S.,& Jasnić, J.. (2023). Antitumor activity of natural pigment violacein against osteosarcoma and rhabdomyosarcoma cell lines. in Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-023-04930-9
UR  - https://hdl.handle.net/21.15107/rcub_imagine_1929
ER  - 

@misc{
author = "Milošević, Emilija and Stanisavljević, Nemanja and Bošković, Srđan and Stamenković, Nemanja and Novković, Mirjana and Bavelloni, Alberto and Cenni, Vittoria and Kojić, Snežana and Jasnić, Jovana",
year = "2023",
journal = "Journal of Cancer Research and Clinical Oncology",
title = "Supplementary data for the article: Milošević, E., Stanisavljević, N., Bošković, S., Stamenković, N., Novković, M., Bavelloni, A., Cenni, V., Kojić, S.,& Jasnić, J.. (2023). Antitumor activity of natural pigment violacein against osteosarcoma and rhabdomyosarcoma cell lines. in Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-023-04930-9",
url = "https://hdl.handle.net/21.15107/rcub_imagine_1929"
}

Milošević, E., Stanisavljević, N., Bošković, S., Stamenković, N., Novković, M., Bavelloni, A., Cenni, V., Kojić, S.,& Jasnić, J.. (2023). Supplementary data for the article: Milošević, E., Stanisavljević, N., Bošković, S., Stamenković, N., Novković, M., Bavelloni, A., Cenni, V., Kojić, S.,& Jasnić, J.. (2023). Antitumor activity of natural pigment violacein against osteosarcoma and rhabdomyosarcoma cell lines. in Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-023-04930-9. in Journal of Cancer Research and Clinical Oncology.
https://hdl.handle.net/21.15107/rcub_imagine_1929

Milošević E, Stanisavljević N, Bošković S, Stamenković N, Novković M, Bavelloni A, Cenni V, Kojić S, Jasnić J. Supplementary data for the article: Milošević, E., Stanisavljević, N., Bošković, S., Stamenković, N., Novković, M., Bavelloni, A., Cenni, V., Kojić, S.,& Jasnić, J.. (2023). Antitumor activity of natural pigment violacein against osteosarcoma and rhabdomyosarcoma cell lines. in Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-023-04930-9. in Journal of Cancer Research and Clinical Oncology. 2023;.
https://hdl.handle.net/21.15107/rcub_imagine_1929 .

Milošević, Emilija, Stanisavljević, Nemanja, Bošković, Srđan, Stamenković, Nemanja, Novković, Mirjana, Bavelloni, Alberto, Cenni, Vittoria, Kojić, Snežana, Jasnić, Jovana, "Supplementary data for the article: Milošević, E., Stanisavljević, N., Bošković, S., Stamenković, N., Novković, M., Bavelloni, A., Cenni, V., Kojić, S.,& Jasnić, J.. (2023). Antitumor activity of natural pigment violacein against osteosarcoma and rhabdomyosarcoma cell lines. in Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-023-04930-9" in Journal of Cancer Research and Clinical Oncology (2023),
https://hdl.handle.net/21.15107/rcub_imagine_1929 .

TY  - CONF
AU  - Milošević, Emilija
AU  - Jasnić, Jovana
AU  - Novković, Mirjana
AU  - Cenni, V.
AU  - Bavelloni, A.
AU  - Kojić, Snežana
PY  - 2023
UR  - https://febs.onlinelibrary.wiley.com/doi/10.1002/1878-0261.13471
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1911
AB  - Introduction: Rhabdomyosarcoma (RMS) is the most common soft tissue
malignancy in children and adolescents. Respecting the age
of the patients and the tumor aggressiveness, investigation
of the molecular mechanisms of RMS tumorigenesis is
essential, most notably due to the possible identification of
novel therapeutic targets. To contribute to a better
understanding of the molecular pathology of RMS, we
investigated ANKRD1 (ankyrin repeat domain 1) gene,
considered a potential RMS diagnostic marker. The
changes in its expression are related to carcinogenesis and
resistance to chemotherapy in several types of tumors.
PB  - Wiley
C3  - Molecular oncology
T1  - Expression profiling of ANKRD1 in rhabdomyosarcoma cell lines
EP  - 197
SP  - 196
VL  - 17
VL  - Supplement 1
DO  - doi.org/10.1002/1878-0261.13471
ER  - 

@conference{
author = "Milošević, Emilija and Jasnić, Jovana and Novković, Mirjana and Cenni, V. and Bavelloni, A. and Kojić, Snežana",
year = "2023",
abstract = "Introduction: Rhabdomyosarcoma (RMS) is the most common soft tissue
malignancy in children and adolescents. Respecting the age
of the patients and the tumor aggressiveness, investigation
of the molecular mechanisms of RMS tumorigenesis is
essential, most notably due to the possible identification of
novel therapeutic targets. To contribute to a better
understanding of the molecular pathology of RMS, we
investigated ANKRD1 (ankyrin repeat domain 1) gene,
considered a potential RMS diagnostic marker. The
changes in its expression are related to carcinogenesis and
resistance to chemotherapy in several types of tumors.",
publisher = "Wiley",
journal = "Molecular oncology",
title = "Expression profiling of ANKRD1 in rhabdomyosarcoma cell lines",
pages = "197-196",
volume = "17, Supplement 1",
doi = "doi.org/10.1002/1878-0261.13471"
}

Milošević, E., Jasnić, J., Novković, M., Cenni, V., Bavelloni, A.,& Kojić, S.. (2023). Expression profiling of ANKRD1 in rhabdomyosarcoma cell lines. in Molecular oncology
Wiley., 17, 196-197.
https://doi.org/doi.org/10.1002/1878-0261.13471

Milošević E, Jasnić J, Novković M, Cenni V, Bavelloni A, Kojić S. Expression profiling of ANKRD1 in rhabdomyosarcoma cell lines. in Molecular oncology. 2023;17:196-197.
doi:doi.org/10.1002/1878-0261.13471 .

Milošević, Emilija, Jasnić, Jovana, Novković, Mirjana, Cenni, V., Bavelloni, A., Kojić, Snežana, "Expression profiling of ANKRD1 in rhabdomyosarcoma cell lines" in Molecular oncology, 17 (2023):196-197,
https://doi.org/doi.org/10.1002/1878-0261.13471 . .

TY  - CONF
AU  - Novković, Mirjana
AU  - Banović Đeri, Bojana
AU  - Todorović, Saša
AU  - Đorđević, Valentina
PY  - 2023
UR  - https://belbi.bg.ac.rs/
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2021
AB  - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global
pandemic, resulting in significant morbidity and mortality worldwide. Understanding the evolutionary
dynamics and genetic diversity of the virus were crucial for virus control and management
strategies. With that aim we conducted genomic surveillance and phylogenetic analysis of
SARS-CoV-2 variants in Serbia, spanning from March 2020 to the end of January 2023.
Sequencing was conducted using three different platforms: Oxford Nanopore, Ion Torrent AmpliSeq
and BGISEQ-500. Consensus sequences obtained using platforms respective software were deposited
in the GISAID database. In this study 2109 good-quality sequences were included (doi.10.55876/
gis8.230411qh). Pangolin and Nextclade software were utilized for clade, lineage and variant
determination, while sequence alignment and construction of the phylogenetic tree was performed
using Nextstrain web-based application.
Variant analysis revealed over 125,000 mutations across the 2109 sequences, of which 38% occurred in
the S protein encoding gene. The most common mutations involved intragenic single nucleotide variants
(88%), followed by intragenic deletions (5%). All sequences were assigned to following 16 clades: 20A,
20B, 20C, 20D, 20E, 20G, 20I, 21J, 21K, 21L, 22A, 22B, 22C, 22D, 22E, and 22F.
Temporal analysis of the variants in Serbia revealed that the Alpha variant was predominant during 2020
and the first three months of 2021. The Delta variant emerged in June 2021, dominating until the end
of December 2021, when Omicron variant was detected for the first time, overtaking the dominance for
the remaining surveillance period. Notably, the Gamma and Epsilon variants were not detected in the
analyzed samples.
Phylogenetic analysis demonstrated that the SARS-CoV-2 variants circulating in Serbia were largely
comparable to the variants found in Europe. However, a slight delay in their emergence was observed,
potentially attributed to a lower travel rate during that period and a decreased frequency of sequencing
in certain months.
PB  - Belgrade : Institute of molecular genetics and genetic engineering
C3  - 4th Belgrade Bioinformatics Conference
T1  - Genomic Surveillance and Phylogenetic Analysis of SARS-CoV-2 Variants in Serbia: Insights into Evolutionary Dynamics and Genetic Diversity
EP  - 81
SP  - 81
VL  - 4
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2021
ER  - 

@conference{
author = "Novković, Mirjana and Banović Đeri, Bojana and Todorović, Saša and Đorđević, Valentina",
year = "2023",
abstract = "The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global
pandemic, resulting in significant morbidity and mortality worldwide. Understanding the evolutionary
dynamics and genetic diversity of the virus were crucial for virus control and management
strategies. With that aim we conducted genomic surveillance and phylogenetic analysis of
SARS-CoV-2 variants in Serbia, spanning from March 2020 to the end of January 2023.
Sequencing was conducted using three different platforms: Oxford Nanopore, Ion Torrent AmpliSeq
and BGISEQ-500. Consensus sequences obtained using platforms respective software were deposited
in the GISAID database. In this study 2109 good-quality sequences were included (doi.10.55876/
gis8.230411qh). Pangolin and Nextclade software were utilized for clade, lineage and variant
determination, while sequence alignment and construction of the phylogenetic tree was performed
using Nextstrain web-based application.
Variant analysis revealed over 125,000 mutations across the 2109 sequences, of which 38% occurred in
the S protein encoding gene. The most common mutations involved intragenic single nucleotide variants
(88%), followed by intragenic deletions (5%). All sequences were assigned to following 16 clades: 20A,
20B, 20C, 20D, 20E, 20G, 20I, 21J, 21K, 21L, 22A, 22B, 22C, 22D, 22E, and 22F.
Temporal analysis of the variants in Serbia revealed that the Alpha variant was predominant during 2020
and the first three months of 2021. The Delta variant emerged in June 2021, dominating until the end
of December 2021, when Omicron variant was detected for the first time, overtaking the dominance for
the remaining surveillance period. Notably, the Gamma and Epsilon variants were not detected in the
analyzed samples.
Phylogenetic analysis demonstrated that the SARS-CoV-2 variants circulating in Serbia were largely
comparable to the variants found in Europe. However, a slight delay in their emergence was observed,
potentially attributed to a lower travel rate during that period and a decreased frequency of sequencing
in certain months.",
publisher = "Belgrade : Institute of molecular genetics and genetic engineering",
journal = "4th Belgrade Bioinformatics Conference",
title = "Genomic Surveillance and Phylogenetic Analysis of SARS-CoV-2 Variants in Serbia: Insights into Evolutionary Dynamics and Genetic Diversity",
pages = "81-81",
volume = "4",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2021"
}

Novković, M., Banović Đeri, B., Todorović, S.,& Đorđević, V.. (2023). Genomic Surveillance and Phylogenetic Analysis of SARS-CoV-2 Variants in Serbia: Insights into Evolutionary Dynamics and Genetic Diversity. in 4th Belgrade Bioinformatics Conference
Belgrade : Institute of molecular genetics and genetic engineering., 4, 81-81.
https://hdl.handle.net/21.15107/rcub_imagine_2021

Novković M, Banović Đeri B, Todorović S, Đorđević V. Genomic Surveillance and Phylogenetic Analysis of SARS-CoV-2 Variants in Serbia: Insights into Evolutionary Dynamics and Genetic Diversity. in 4th Belgrade Bioinformatics Conference. 2023;4:81-81.
https://hdl.handle.net/21.15107/rcub_imagine_2021 .

Novković, Mirjana, Banović Đeri, Bojana, Todorović, Saša, Đorđević, Valentina, "Genomic Surveillance and Phylogenetic Analysis of SARS-CoV-2 Variants in Serbia: Insights into Evolutionary Dynamics and Genetic Diversity" in 4th Belgrade Bioinformatics Conference, 4 (2023):81-81,
https://hdl.handle.net/21.15107/rcub_imagine_2021 .

TY  - CONF
AU  - Bačković, Dragana
AU  - Novković, Mirjana
AU  - Matić, Dragan
AU  - Antonijević, Nebojša
AU  - Strugarević, Evgenija
AU  - Kovač, Mirjana
AU  - Kušić-Tišma, Jelena
AU  - Rakićević, Ljiljana
AU  - Radojković, Dragica
PY  - 2021
UR  - https://www.uksrb.rs/en/magazine/archive/heart-and-blood-vessels-number-32021
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2344
AB  - Introduction. Despite proven clinical effect of clopidogrel, a
considerable number of patients do not have an adequate
response to this type of medication. Problems during therapy occur in the form of resistance, which is present in 11%
of patients or bleeding that occurs in about 9% of patients.
Pharmacogenomics studies demonstrated that variants of
the CYP2C19 gene significantly influence the interindividual heterogenity of the clopidogrel response. The American
Heart Association, US Food and Drug Administration and the
European Medicines Agency, cite the CYP2C19 gene as a significant factor which influences patients response to clopidogrel. Further, it has been shown that the contribution of
genetic and non-genetic factors affecting clopidogrel therapy
may vary between patients from different populations, which
justifies conducting population-specific studies.
The aim. The aim of our study was to examine the significance
of the CYP2C19*2 and the CYP2C19*17 variants in the individual response to clopidogrel, in Serbian patients.
Methods. The study involved 108 patients with carotid artery
stenosis who underwent endarterectomy and received clopidogrel for at least 30 days after the intervention. Also, 120
patients with myocardial infarction receiving clopidogrel after PCI (percutaneous coronary intervention) were included.
Commercial tests were used for standard laboratory testing.
Allelic discrimination was performed after Sanger sequencing.
Results were analysed using statistical tests.
Results. In patients undergoing endarterectomy CYP2C19*2
carriers had a higher risk for being clopidogrel low-responder
in comparison with non-carriers (1.250, 95% CI 1.695–1.658,
P<0.01). In the group of patients undergoing PCI, risk for reinfarction in patients who were carriers of CYP2C19*2 was higher
compared to patients with wild type genotype (OR 5.355, 95%
CI 0.955-31.08; P=0.038). Variant CYP2C19*17 showed no association with variations in response to clopidogrel therapy.
Conclusion. The CYP2C19*2 variant shows significant association with a poor response to clopidogrel and it should be
considered when planning therapy.
PB  - Beograd : Udruženje kardiologa Srbije
C3  - Heart and Blood Vessels
T1  - Analysis of the association of the CYP2C19 variants with the effects of clopidogrel therapy in patients underwent to carotid endarterectomy
IS  - 3
VL  - 40
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2344
ER  - 

@conference{
author = "Bačković, Dragana and Novković, Mirjana and Matić, Dragan and Antonijević, Nebojša and Strugarević, Evgenija and Kovač, Mirjana and Kušić-Tišma, Jelena and Rakićević, Ljiljana and Radojković, Dragica",
year = "2021",
abstract = "Introduction. Despite proven clinical effect of clopidogrel, a
considerable number of patients do not have an adequate
response to this type of medication. Problems during therapy occur in the form of resistance, which is present in 11%
of patients or bleeding that occurs in about 9% of patients.
Pharmacogenomics studies demonstrated that variants of
the CYP2C19 gene significantly influence the interindividual heterogenity of the clopidogrel response. The American
Heart Association, US Food and Drug Administration and the
European Medicines Agency, cite the CYP2C19 gene as a significant factor which influences patients response to clopidogrel. Further, it has been shown that the contribution of
genetic and non-genetic factors affecting clopidogrel therapy
may vary between patients from different populations, which
justifies conducting population-specific studies.
The aim. The aim of our study was to examine the significance
of the CYP2C19*2 and the CYP2C19*17 variants in the individual response to clopidogrel, in Serbian patients.
Methods. The study involved 108 patients with carotid artery
stenosis who underwent endarterectomy and received clopidogrel for at least 30 days after the intervention. Also, 120
patients with myocardial infarction receiving clopidogrel after PCI (percutaneous coronary intervention) were included.
Commercial tests were used for standard laboratory testing.
Allelic discrimination was performed after Sanger sequencing.
Results were analysed using statistical tests.
Results. In patients undergoing endarterectomy CYP2C19*2
carriers had a higher risk for being clopidogrel low-responder
in comparison with non-carriers (1.250, 95% CI 1.695–1.658,
P<0.01). In the group of patients undergoing PCI, risk for reinfarction in patients who were carriers of CYP2C19*2 was higher
compared to patients with wild type genotype (OR 5.355, 95%
CI 0.955-31.08; P=0.038). Variant CYP2C19*17 showed no association with variations in response to clopidogrel therapy.
Conclusion. The CYP2C19*2 variant shows significant association with a poor response to clopidogrel and it should be
considered when planning therapy.",
publisher = "Beograd : Udruženje kardiologa Srbije",
journal = "Heart and Blood Vessels",
title = "Analysis of the association of the CYP2C19 variants with the effects of clopidogrel therapy in patients underwent to carotid endarterectomy",
number = "3",
volume = "40",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2344"
}

Bačković, D., Novković, M., Matić, D., Antonijević, N., Strugarević, E., Kovač, M., Kušić-Tišma, J., Rakićević, L.,& Radojković, D.. (2021). Analysis of the association of the CYP2C19 variants with the effects of clopidogrel therapy in patients underwent to carotid endarterectomy. in Heart and Blood Vessels
Beograd : Udruženje kardiologa Srbije., 40(3).
https://hdl.handle.net/21.15107/rcub_imagine_2344

Bačković D, Novković M, Matić D, Antonijević N, Strugarević E, Kovač M, Kušić-Tišma J, Rakićević L, Radojković D. Analysis of the association of the CYP2C19 variants with the effects of clopidogrel therapy in patients underwent to carotid endarterectomy. in Heart and Blood Vessels. 2021;40(3).
https://hdl.handle.net/21.15107/rcub_imagine_2344 .

Bačković, Dragana, Novković, Mirjana, Matić, Dragan, Antonijević, Nebojša, Strugarević, Evgenija, Kovač, Mirjana, Kušić-Tišma, Jelena, Rakićević, Ljiljana, Radojković, Dragica, "Analysis of the association of the CYP2C19 variants with the effects of clopidogrel therapy in patients underwent to carotid endarterectomy" in Heart and Blood Vessels, 40, no. 3 (2021),
https://hdl.handle.net/21.15107/rcub_imagine_2344 .

TY  - JOUR
AU  - Stamenković, Nemanja
AU  - Jasnić, Jovana
AU  - Novković, Mirjana
AU  - Milošević, Emilija
AU  - Bošković, Srđan
AU  - Kojić, Ana
AU  - Popić, Kristina
AU  - Stanković, Marija
AU  - Wang, Yajun
AU  - Milenković, Sanja
AU  - Radojković, Dragica
AU  - Ma, Guada
AU  - Kojić, Snežana
PY  - 2020
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1307
AB  - Striated muscle signaling protein and transcriptional regulator ANKRD2 participates in myogenesis, myogenic differentiation, muscle adaptation and stress response. It is preferentially expressed in slow, oxidative fibers of mammalian skeletal muscle. In this study, we report on characterization of chickenANKRD2. The chickenANKRD2coding region contains 1002 bp and encodes a 334-amino acid protein which shares approximately 58% identity with human and mouse orthologs, mostly in the conserved region of ankyrin repeats. Comprehensive analysis of theANKRD2gene and protein expression in adult chicken demonstrated its predominant expression in red muscles of thigh and drumstick, compared to white muscle. It was not detected in heart and white pectoral muscle. Uneven expression of ANKRD2 in chicken skeletal muscles, observed by immunohistochemistry, was attributed to its selective expression in slow, oxidative, type I and fast, oxidative-glycolytic, type IIA myofibers. Association of chickenANKRD2with phenotypic differences between red and white muscles points to its potential role in the process of myofiber-type specification. In addition to expression in slow oxidative myofibers, as demonstrated for mammalian protein, chicken ANKRD2 was also detected in fast fibers with mixed oxidative and glycolytic metabolism. This finding suggests thatANKRD2is responsive to metabolic differences between types of avian myofibers and orientates future studies towards investigation of its role in molecular mechanisms of myofiber-type-specific gene expression.
PB  - Springer, New York
T2  - Histochemistry and Cell Biology
T1  - Cloning and expression profiling of muscle regulator ANKRD2 in domestic chickenGallus gallus
EP  - 396
IS  - 4
SP  - 383
VL  - 154
DO  - 10.1007/s00418-020-01899-1
ER  - 

@article{
author = "Stamenković, Nemanja and Jasnić, Jovana and Novković, Mirjana and Milošević, Emilija and Bošković, Srđan and Kojić, Ana and Popić, Kristina and Stanković, Marija and Wang, Yajun and Milenković, Sanja and Radojković, Dragica and Ma, Guada and Kojić, Snežana",
year = "2020",
abstract = "Striated muscle signaling protein and transcriptional regulator ANKRD2 participates in myogenesis, myogenic differentiation, muscle adaptation and stress response. It is preferentially expressed in slow, oxidative fibers of mammalian skeletal muscle. In this study, we report on characterization of chickenANKRD2. The chickenANKRD2coding region contains 1002 bp and encodes a 334-amino acid protein which shares approximately 58% identity with human and mouse orthologs, mostly in the conserved region of ankyrin repeats. Comprehensive analysis of theANKRD2gene and protein expression in adult chicken demonstrated its predominant expression in red muscles of thigh and drumstick, compared to white muscle. It was not detected in heart and white pectoral muscle. Uneven expression of ANKRD2 in chicken skeletal muscles, observed by immunohistochemistry, was attributed to its selective expression in slow, oxidative, type I and fast, oxidative-glycolytic, type IIA myofibers. Association of chickenANKRD2with phenotypic differences between red and white muscles points to its potential role in the process of myofiber-type specification. In addition to expression in slow oxidative myofibers, as demonstrated for mammalian protein, chicken ANKRD2 was also detected in fast fibers with mixed oxidative and glycolytic metabolism. This finding suggests thatANKRD2is responsive to metabolic differences between types of avian myofibers and orientates future studies towards investigation of its role in molecular mechanisms of myofiber-type-specific gene expression.",
publisher = "Springer, New York",
journal = "Histochemistry and Cell Biology",
title = "Cloning and expression profiling of muscle regulator ANKRD2 in domestic chickenGallus gallus",
pages = "396-383",
number = "4",
volume = "154",
doi = "10.1007/s00418-020-01899-1"
}

Stamenković, N., Jasnić, J., Novković, M., Milošević, E., Bošković, S., Kojić, A., Popić, K., Stanković, M., Wang, Y., Milenković, S., Radojković, D., Ma, G.,& Kojić, S.. (2020). Cloning and expression profiling of muscle regulator ANKRD2 in domestic chickenGallus gallus. in Histochemistry and Cell Biology
Springer, New York., 154(4), 383-396.
https://doi.org/10.1007/s00418-020-01899-1

Stamenković N, Jasnić J, Novković M, Milošević E, Bošković S, Kojić A, Popić K, Stanković M, Wang Y, Milenković S, Radojković D, Ma G, Kojić S. Cloning and expression profiling of muscle regulator ANKRD2 in domestic chickenGallus gallus. in Histochemistry and Cell Biology. 2020;154(4):383-396.
doi:10.1007/s00418-020-01899-1 .

Stamenković, Nemanja, Jasnić, Jovana, Novković, Mirjana, Milošević, Emilija, Bošković, Srđan, Kojić, Ana, Popić, Kristina, Stanković, Marija, Wang, Yajun, Milenković, Sanja, Radojković, Dragica, Ma, Guada, Kojić, Snežana, "Cloning and expression profiling of muscle regulator ANKRD2 in domestic chickenGallus gallus" in Histochemistry and Cell Biology, 154, no. 4 (2020):383-396,
https://doi.org/10.1007/s00418-020-01899-1 . .

TY  - THES
AU  - Novković, Mirjana
PY  - 2018
UR  - http://eteze.bg.ac.rs/application/showtheses?thesesId=6572
UR  - https://nardus.mpn.gov.rs/handle/123456789/10712
UR  - https://fedorabg.bg.ac.rs/fedora/get/o:19349/bdef:Content/download
UR  - http://vbs.rs/scripts/cobiss?command=DISPLAY&base=70036&RID=1025209010
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/51
AB  - Klopidogrel je antiagregacioni lek koji je sa aspirinom, u sklopu dvojne antiagregacione terapije, indikovan u stanjima koja nose rizik od ishemijskih događaja i tromboembolijskih komplikacija. Postoji velika interindividualna varijabilnost u odgovoru na klopidogrel. Značajan broj pacijenata kao posledicu neadekvatnog odgovora na terapiju može iskusiti različita neželjena dejstva. Kod oko 9% pacijenata koji su na terapiji klopidogrelom javlja se krvarenje kao neželjeni efekat. Ono samo po sebi može biti životno ugrožavajuće, a sekundarno može biti povezano sa pojavom ishemijskih događaja. Uzroci varijabilnosti u odgovoru na terapiju klopidogrelom, mogu biti kako stečeni, tako i posledica genetičkih faktora. Među genetičkim faktorima najznačajniji doprinos ima gen za enzim CYP2C19 koji je neophodan u procesu konverzije klopidogrela u aktivnu formu leka. Zbog toga su varijante CYP2C19 gena najčešće razmatrane u okviru farmakogenetike klopidogrela. Od posebnog kliničkog značaja su varijante rs4244285 (c.681G>A; CYP2C19*2) i rs4986893 (c.636G>A; CYP2C19*3), koje su povezane sa oslabljenim odgovorom na klopidogrel. Promotorska varijanta rs12248560 (c.-806C>T, CYP2C19*17) se dovodi u vezu sa pojačanim stepenom inhibicije trombocita i povišenim rizikom od krvarenja kod pacijenata na terapiji klopidogrelom. U fokusu ove studije bilo je ispitivanje uticaja CYP2C19 gena na pojavu pojačanog odgovora na klopidogrel koje vodi povišenom riziku od krvarenja. Istraživanje je sprovedeno u grupi pacijenata koji su pretrpeli infarkt miokarda i bili podvrgnuti perkutanoj koronarnoj intervenciji (PCI), kao i grupi pacijenata sa stenozom karotida koji su podvrgnuti karotidnoj endarterektomiji (CEA). U studiji su analizirane promotorske varijante rs12248560 (c.-806C>T, CYP2C19*17) i rs11568732 (c.-889T>G, CYP2C19*20) za koje su literaturni podaci i naši preliminarni rezultati pokazali da mogu biti povezane sa pojačanim odgovorom na klopidogrel. Dodatno su analizirane egzonske varijante rs4244285 (c.681G>A; CYP2C19*2) i rs4986893 (c.636G>A, CYP2C19*3) zbog mogućeg uticaja na efekte promotorskih varijanti. Zbog oskudnosti podataka koji se odnose na promotorsku varijantu rs11568732 (c.-889T>G, CYP2C19*20), jedan od ciljeva studije bio je da se u in vitro uslovima ispita njen funkcijski značaj...
AB  - Wide inter-individual variability in clopidogrel response has been reported. Significant number of patients with inadequate response to clopidogrel experience different adverse effects. Bleeding as an adverse event occurs in about 9% of patients on clopidogrel therapy. It can be life threatening and secondarily, related to higher risk of ischemic events. Variability in clopidogrel response may be explained by different non-genetic and genetic factors. Among genetic factors, the most important role has CYP2C19 gene encoding enzyme responsible for conversion of clopidogrel to its active form. Hence, CYP2C19 gene variants are the most commonly investigated genetic variants related to clopidogrel pharmacogenetics. Clinically, the most relevant variants are rs4244285 (c.681G>A; CYP2C19*2) and rs4986893 (c.636G>A; CYP2C19*3) which lead to clopidogrel poor response. Additionally, promoter variant rs12248560 (c.-806C>T, CYP2C19*17) is associated with elevated platelet inhibition and increased risk of bleeding in patients on clopidogrel. This study was focused on investigating role of CYP2C19 gene in clopidogrel hyper-responsiveness which increases the risk of bleeding. This study was conducted in a group of patients with acute myocardial infarction who underwent percutaneous coronary intervention (PCI) as well as in patients with carotid stenosis who underwent carotid endarterectomy (CEA). In this study we examined two promoter rs12248560 (CYP2C19*17) and rs11568732 (CYP2C19*20) variants, for which literature and our preliminary results showed to be associated with elevated clopidogrel response. Additionally, we analyzed exonic variants rs4244285 (c.681G>A; CYP2C19*2) and rs4986893 (c.636G>A, CYP2C19*3) considering their potential influence on the promoter variants’ effects. Since literature data on rs11568732 (c.-889T>G, CYP2C19*20) variant is scarce, we aimed to investigate its functional significance. Further, one of our aims was the anlysis of the relevant CYP2C19 variants regarding clopidogrel therapy, which can be used to rationalize current protocols for antiplatelet therapy in Serbia...
PB  - Univerzitet u Beogradu, Biološki fakultet
T1  - Analiza promotorskih varijanti genaCYP2C19 i njihova uloga u predviđanju terapijskog odgovora na lek klopidogrel kod pacijenata sa infarktom miokarda i stenozom kariotida
T1  - Analysis of variants in the promoter region of CYP2C19 gene and their role in prediction of clopidogrel response in patients with myocardial infarcition and carotid stenosis
UR  - https://hdl.handle.net/21.15107/rcub_nardus_10712
ER  - 

@phdthesis{
author = "Novković, Mirjana",
year = "2018",
abstract = "Klopidogrel je antiagregacioni lek koji je sa aspirinom, u sklopu dvojne antiagregacione terapije, indikovan u stanjima koja nose rizik od ishemijskih događaja i tromboembolijskih komplikacija. Postoji velika interindividualna varijabilnost u odgovoru na klopidogrel. Značajan broj pacijenata kao posledicu neadekvatnog odgovora na terapiju može iskusiti različita neželjena dejstva. Kod oko 9% pacijenata koji su na terapiji klopidogrelom javlja se krvarenje kao neželjeni efekat. Ono samo po sebi može biti životno ugrožavajuće, a sekundarno može biti povezano sa pojavom ishemijskih događaja. Uzroci varijabilnosti u odgovoru na terapiju klopidogrelom, mogu biti kako stečeni, tako i posledica genetičkih faktora. Među genetičkim faktorima najznačajniji doprinos ima gen za enzim CYP2C19 koji je neophodan u procesu konverzije klopidogrela u aktivnu formu leka. Zbog toga su varijante CYP2C19 gena najčešće razmatrane u okviru farmakogenetike klopidogrela. Od posebnog kliničkog značaja su varijante rs4244285 (c.681G>A; CYP2C19*2) i rs4986893 (c.636G>A; CYP2C19*3), koje su povezane sa oslabljenim odgovorom na klopidogrel. Promotorska varijanta rs12248560 (c.-806C>T, CYP2C19*17) se dovodi u vezu sa pojačanim stepenom inhibicije trombocita i povišenim rizikom od krvarenja kod pacijenata na terapiji klopidogrelom. U fokusu ove studije bilo je ispitivanje uticaja CYP2C19 gena na pojavu pojačanog odgovora na klopidogrel koje vodi povišenom riziku od krvarenja. Istraživanje je sprovedeno u grupi pacijenata koji su pretrpeli infarkt miokarda i bili podvrgnuti perkutanoj koronarnoj intervenciji (PCI), kao i grupi pacijenata sa stenozom karotida koji su podvrgnuti karotidnoj endarterektomiji (CEA). U studiji su analizirane promotorske varijante rs12248560 (c.-806C>T, CYP2C19*17) i rs11568732 (c.-889T>G, CYP2C19*20) za koje su literaturni podaci i naši preliminarni rezultati pokazali da mogu biti povezane sa pojačanim odgovorom na klopidogrel. Dodatno su analizirane egzonske varijante rs4244285 (c.681G>A; CYP2C19*2) i rs4986893 (c.636G>A, CYP2C19*3) zbog mogućeg uticaja na efekte promotorskih varijanti. Zbog oskudnosti podataka koji se odnose na promotorsku varijantu rs11568732 (c.-889T>G, CYP2C19*20), jedan od ciljeva studije bio je da se u in vitro uslovima ispita njen funkcijski značaj..., Wide inter-individual variability in clopidogrel response has been reported. Significant number of patients with inadequate response to clopidogrel experience different adverse effects. Bleeding as an adverse event occurs in about 9% of patients on clopidogrel therapy. It can be life threatening and secondarily, related to higher risk of ischemic events. Variability in clopidogrel response may be explained by different non-genetic and genetic factors. Among genetic factors, the most important role has CYP2C19 gene encoding enzyme responsible for conversion of clopidogrel to its active form. Hence, CYP2C19 gene variants are the most commonly investigated genetic variants related to clopidogrel pharmacogenetics. Clinically, the most relevant variants are rs4244285 (c.681G>A; CYP2C19*2) and rs4986893 (c.636G>A; CYP2C19*3) which lead to clopidogrel poor response. Additionally, promoter variant rs12248560 (c.-806C>T, CYP2C19*17) is associated with elevated platelet inhibition and increased risk of bleeding in patients on clopidogrel. This study was focused on investigating role of CYP2C19 gene in clopidogrel hyper-responsiveness which increases the risk of bleeding. This study was conducted in a group of patients with acute myocardial infarction who underwent percutaneous coronary intervention (PCI) as well as in patients with carotid stenosis who underwent carotid endarterectomy (CEA). In this study we examined two promoter rs12248560 (CYP2C19*17) and rs11568732 (CYP2C19*20) variants, for which literature and our preliminary results showed to be associated with elevated clopidogrel response. Additionally, we analyzed exonic variants rs4244285 (c.681G>A; CYP2C19*2) and rs4986893 (c.636G>A, CYP2C19*3) considering their potential influence on the promoter variants’ effects. Since literature data on rs11568732 (c.-889T>G, CYP2C19*20) variant is scarce, we aimed to investigate its functional significance. Further, one of our aims was the anlysis of the relevant CYP2C19 variants regarding clopidogrel therapy, which can be used to rationalize current protocols for antiplatelet therapy in Serbia...",
publisher = "Univerzitet u Beogradu, Biološki fakultet",
title = "Analiza promotorskih varijanti genaCYP2C19 i njihova uloga u predviđanju terapijskog odgovora na lek klopidogrel kod pacijenata sa infarktom miokarda i stenozom kariotida, Analysis of variants in the promoter region of CYP2C19 gene and their role in prediction of clopidogrel response in patients with myocardial infarcition and carotid stenosis",
url = "https://hdl.handle.net/21.15107/rcub_nardus_10712"
}

Novković, M.. (2018). Analiza promotorskih varijanti genaCYP2C19 i njihova uloga u predviđanju terapijskog odgovora na lek klopidogrel kod pacijenata sa infarktom miokarda i stenozom kariotida. 
Univerzitet u Beogradu, Biološki fakultet..
https://hdl.handle.net/21.15107/rcub_nardus_10712

Novković M. Analiza promotorskih varijanti genaCYP2C19 i njihova uloga u predviđanju terapijskog odgovora na lek klopidogrel kod pacijenata sa infarktom miokarda i stenozom kariotida. 2018;.
https://hdl.handle.net/21.15107/rcub_nardus_10712 .

Novković, Mirjana, "Analiza promotorskih varijanti genaCYP2C19 i njihova uloga u predviđanju terapijskog odgovora na lek klopidogrel kod pacijenata sa infarktom miokarda i stenozom kariotida" (2018),
https://hdl.handle.net/21.15107/rcub_nardus_10712 .

TY  - JOUR
AU  - Novković, Mirjana
AU  - Matić, Dragan
AU  - Kušić-Tišma, Jelena
AU  - Antonijević, Nebojša
AU  - Radojković, Dragica
AU  - Rakićević, Ljiljana
PY  - 2018
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1187
AB  - Bleeding is one of the possible adverse events during clopidogrel therapy. The CYP2C19 gene is the most significant genetic factor which influences response to clopidogrel treatment. We aimed to examine the contribution of the CYP2C19 gene to bleeding occurrence during clopidogrel therapy in Serbian patients with ST segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). This case-control study included 53 patients who experienced bleeding and 55 patients without bleeding. Bleeding events were defined and classified using the Bleeding Academic Research Consortium (BARC) criteria. All patients were prescribed daily doses of clopidogrel during the 1-year follow-up after PCI. The CYP2C19*17 (c.-806C  gt  T, rs12248560), rs11568732 (c.-889T  gt  G, CYP2C19*20), CYP2C19*2 (c.681G  gt  A; rs4244285) and CYP2C19*3 (c.636G  gt  A; rs4986893) variants were analysed in all 108 patients. Additionally, sequencing of all nine exons, 5'UTR and 3'UTR in the rs11568732 carriers was performed. Association between bleeding (BARC type ae lt yen gt  2) and the CYP2C19*17 variant was not observed [odds ratio (OR), 0.53; 95% confidence interval (CI), 0.2-1.1; p = 0.107). The rs11568732 variant showed significant association with bleeding (OR, 3.7; 95% CI, 1.12-12.44; p = 0.025). Also, we found that the rs11568732 variant appears independently of haplotype CYP2C19*3B, which is contrary to the previous findings. Our results indicate the absence of CYP2C19*17 influence and turn the attention to the potential significance of the rs11568732 variant in terms of adverse effects of clopidogrel. However, it is necessary to conduct an independent conformation study in order to verify this finding. Also, an analysis of the functional implication of the rs11568732 variant is necessary in order to confirm the significance of this variant, both in relation to its influence on gene expression and in relation to its medical significance.
PB  - Springer Heidelberg, Heidelberg
T2  - European Journal of Clinical Pharmacology
T1  - Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel
EP  - 451
IS  - 4
SP  - 443
VL  - 74
DO  - 10.1007/s00228-017-2401-5
ER  - 

@article{
author = "Novković, Mirjana and Matić, Dragan and Kušić-Tišma, Jelena and Antonijević, Nebojša and Radojković, Dragica and Rakićević, Ljiljana",
year = "2018",
abstract = "Bleeding is one of the possible adverse events during clopidogrel therapy. The CYP2C19 gene is the most significant genetic factor which influences response to clopidogrel treatment. We aimed to examine the contribution of the CYP2C19 gene to bleeding occurrence during clopidogrel therapy in Serbian patients with ST segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). This case-control study included 53 patients who experienced bleeding and 55 patients without bleeding. Bleeding events were defined and classified using the Bleeding Academic Research Consortium (BARC) criteria. All patients were prescribed daily doses of clopidogrel during the 1-year follow-up after PCI. The CYP2C19*17 (c.-806C  gt  T, rs12248560), rs11568732 (c.-889T  gt  G, CYP2C19*20), CYP2C19*2 (c.681G  gt  A; rs4244285) and CYP2C19*3 (c.636G  gt  A; rs4986893) variants were analysed in all 108 patients. Additionally, sequencing of all nine exons, 5'UTR and 3'UTR in the rs11568732 carriers was performed. Association between bleeding (BARC type ae lt yen gt  2) and the CYP2C19*17 variant was not observed [odds ratio (OR), 0.53; 95% confidence interval (CI), 0.2-1.1; p = 0.107). The rs11568732 variant showed significant association with bleeding (OR, 3.7; 95% CI, 1.12-12.44; p = 0.025). Also, we found that the rs11568732 variant appears independently of haplotype CYP2C19*3B, which is contrary to the previous findings. Our results indicate the absence of CYP2C19*17 influence and turn the attention to the potential significance of the rs11568732 variant in terms of adverse effects of clopidogrel. However, it is necessary to conduct an independent conformation study in order to verify this finding. Also, an analysis of the functional implication of the rs11568732 variant is necessary in order to confirm the significance of this variant, both in relation to its influence on gene expression and in relation to its medical significance.",
publisher = "Springer Heidelberg, Heidelberg",
journal = "European Journal of Clinical Pharmacology",
title = "Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel",
pages = "451-443",
number = "4",
volume = "74",
doi = "10.1007/s00228-017-2401-5"
}

Novković, M., Matić, D., Kušić-Tišma, J., Antonijević, N., Radojković, D.,& Rakićević, L.. (2018). Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel. in European Journal of Clinical Pharmacology
Springer Heidelberg, Heidelberg., 74(4), 443-451.
https://doi.org/10.1007/s00228-017-2401-5

Novković M, Matić D, Kušić-Tišma J, Antonijević N, Radojković D, Rakićević L. Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel. in European Journal of Clinical Pharmacology. 2018;74(4):443-451.
doi:10.1007/s00228-017-2401-5 .

Novković, Mirjana, Matić, Dragan, Kušić-Tišma, Jelena, Antonijević, Nebojša, Radojković, Dragica, Rakićević, Ljiljana, "Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel" in European Journal of Clinical Pharmacology, 74, no. 4 (2018):443-451,
https://doi.org/10.1007/s00228-017-2401-5 . .

TY  - JOUR
AU  - Mitropoulou, Christina
AU  - Fragoulakis, Vasilios
AU  - Rakićević, Ljiljana
AU  - Novković, Mirjana
AU  - Vozikis, Athanassios
AU  - Matić, Dragan M.
AU  - Antonijević, Nebojša
AU  - Radojković, Dragica 
AU  - van Schaik, Ron H.
AU  - Patrinos, George P.
PY  - 2016
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/965
AB  - Introduction: Clopidogrel, which is activated by the CYP2C19 enzyme, is among the drugs for which all major regulatory agencies recommend genetic testing to be performed to identify a patient's CYP2C19 genotype in order to determine the optimal antiplatelet therapeutic scheme. The CYP2C19*2 and CYP2C19*3 variants are loss-of-function alleles, leading to abolished CYP2C19 function and thus have the risk of thrombotic events for carriers of these alleles on standard dosages, while the CYP2C19*17 allele results in CYP2C19 hyperactivity. Aims: Here, we report our findings from a retrospective study to assess whether genotyping for the CYP2C19*2 allele was cost effective for myocardial infarction patients receiving clopidogrel treatment in the Serbian population compared with the nongenotype-guided treatment. Results: We found that 59.3% of the CYP2C19*1/*1 patients had a minor or major bleeding event versus 42.85% of the CYP2C19*1/*2 and *2/*2, while a reinfarction event occurred only in 2.3% of the CYP21C9*1/*1 patients, compared with 11.2% of the CYP2C19*1/*2 and CYP2C19*2/*2 patients. There were subtle differences between the two patient groups, as far as the duration of hospitalization and rehabilitation is concerned, in favor of the CYP2C19*1/*1 group. The mean cost for the CYP2C19*1/*1 patients was estimated at (sic)2547 versus (sic)2799 in the CYP2C19*1/*2 and CYP2C19*2/*2 patients. Furthermore, based on the overall CYP2C19*1/*2 genotype frequencies in the Serbian population, a break-even point analysis indicated that performing the genetic test prior to drug prescription represents a cost-saving option, saving (sic)13 per person on average. Conclusion: Overall, our data demonstrate that pharmacogenomics-guided clopidogrel treatment may represent a cost-saving approach for the management of myocardial infarction patients undergoing primary percutaneous coronary intervention in Serbia.
PB  - Future Medicine Ltd, London
T2  - Pharmacogenomics
T1  - Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention
EP  - 1784
IS  - 16
SP  - 1775
VL  - 17
DO  - 10.2217/pgs-2016-0052
ER  - 

@article{
author = "Mitropoulou, Christina and Fragoulakis, Vasilios and Rakićević, Ljiljana and Novković, Mirjana and Vozikis, Athanassios and Matić, Dragan M. and Antonijević, Nebojša and Radojković, Dragica  and van Schaik, Ron H. and Patrinos, George P.",
year = "2016",
abstract = "Introduction: Clopidogrel, which is activated by the CYP2C19 enzyme, is among the drugs for which all major regulatory agencies recommend genetic testing to be performed to identify a patient's CYP2C19 genotype in order to determine the optimal antiplatelet therapeutic scheme. The CYP2C19*2 and CYP2C19*3 variants are loss-of-function alleles, leading to abolished CYP2C19 function and thus have the risk of thrombotic events for carriers of these alleles on standard dosages, while the CYP2C19*17 allele results in CYP2C19 hyperactivity. Aims: Here, we report our findings from a retrospective study to assess whether genotyping for the CYP2C19*2 allele was cost effective for myocardial infarction patients receiving clopidogrel treatment in the Serbian population compared with the nongenotype-guided treatment. Results: We found that 59.3% of the CYP2C19*1/*1 patients had a minor or major bleeding event versus 42.85% of the CYP2C19*1/*2 and *2/*2, while a reinfarction event occurred only in 2.3% of the CYP21C9*1/*1 patients, compared with 11.2% of the CYP2C19*1/*2 and CYP2C19*2/*2 patients. There were subtle differences between the two patient groups, as far as the duration of hospitalization and rehabilitation is concerned, in favor of the CYP2C19*1/*1 group. The mean cost for the CYP2C19*1/*1 patients was estimated at (sic)2547 versus (sic)2799 in the CYP2C19*1/*2 and CYP2C19*2/*2 patients. Furthermore, based on the overall CYP2C19*1/*2 genotype frequencies in the Serbian population, a break-even point analysis indicated that performing the genetic test prior to drug prescription represents a cost-saving option, saving (sic)13 per person on average. Conclusion: Overall, our data demonstrate that pharmacogenomics-guided clopidogrel treatment may represent a cost-saving approach for the management of myocardial infarction patients undergoing primary percutaneous coronary intervention in Serbia.",
publisher = "Future Medicine Ltd, London",
journal = "Pharmacogenomics",
title = "Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention",
pages = "1784-1775",
number = "16",
volume = "17",
doi = "10.2217/pgs-2016-0052"
}

Mitropoulou, C., Fragoulakis, V., Rakićević, L., Novković, M., Vozikis, A., Matić, D. M., Antonijević, N., Radojković, D., van Schaik, R. H.,& Patrinos, G. P.. (2016). Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention. in Pharmacogenomics
Future Medicine Ltd, London., 17(16), 1775-1784.
https://doi.org/10.2217/pgs-2016-0052

Mitropoulou C, Fragoulakis V, Rakićević L, Novković M, Vozikis A, Matić DM, Antonijević N, Radojković D, van Schaik RH, Patrinos GP. Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention. in Pharmacogenomics. 2016;17(16):1775-1784.
doi:10.2217/pgs-2016-0052 .

Mitropoulou, Christina, Fragoulakis, Vasilios, Rakićević, Ljiljana, Novković, Mirjana, Vozikis, Athanassios, Matić, Dragan M., Antonijević, Nebojša, Radojković, Dragica , van Schaik, Ron H., Patrinos, George P., "Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention" in Pharmacogenomics, 17, no. 16 (2016):1775-1784,
https://doi.org/10.2217/pgs-2016-0052 . .

TY  - JOUR
AU  - Backović, Dragana
AU  - Ignjatović, Svetlana
AU  - Rakićević, Ljiljana
AU  - Novković, Mirjana
AU  - Kušić-Tišma, Jelena
AU  - Radojković, Dragica
AU  - Strugarević, Evgenija
AU  - Calija, Branko
AU  - Radak, Djordje
AU  - Kovač, Mirjana
PY  - 2016
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/920
AB  - Objectives: A considerable number of patients do not achieve an adequate response to clopidogrel. Our study aimed to evaluate genetic and non-genetic factors as possible risks for clopidogrel high on-treatment platelet reactivity (HTPR) in patients (n=112) with carotid artery stenosis undergoing endarterectomy (CEA). Methods: Using multiple-electrode impedance aggregometry (MEA) the antiplatelet effectiveness of clopidogrel was measured after 24 h, 7 and 30 days of clopidogrel treatment, which was introduced after elective CEA at a dose of 75 mg daily, for at least 30 days. Results: HTPR was observed among 25% patients after clopidogrel therapy for 30 days. Further analysis showed that 53.3% of patients carrying the CYP2C19*2 gene variant had clopidogrel-HTPR, while in the wild type group there were 14.6% (p lt 0.001). Multivariate logistic regression analysis identified the CYP2C19*2 variant allele (OR 4.384; 95% CI 1.296-14.833, p=0.017) and high total cholesterol level (OR 2.090; 95% CI 1.263-3.459, p=0.004) as the only independent risk factors for clopidogrel-HTPR. Conclusion: The CYP2C19*2 gene variant and high total cholesterol level were major factors for clopidogrel-HTPR in patients with carotid artery stenosis undergoing CEA.
PB  - Bentham Science Publ Ltd, Sharjah
T2  - Current Vascular Pharmacology
T1  - Clopidogrel High On-Treatment Platelet Reactivity in Patients with Carotid Artery Stenosis Undergoing Endarterectomy. A Pilot Study
EP  - 569
IS  - 6
SP  - 563
VL  - 14
DO  - 10.2174/1570161114666160714103148
ER  - 

@article{
author = "Backović, Dragana and Ignjatović, Svetlana and Rakićević, Ljiljana and Novković, Mirjana and Kušić-Tišma, Jelena and Radojković, Dragica and Strugarević, Evgenija and Calija, Branko and Radak, Djordje and Kovač, Mirjana",
year = "2016",
abstract = "Objectives: A considerable number of patients do not achieve an adequate response to clopidogrel. Our study aimed to evaluate genetic and non-genetic factors as possible risks for clopidogrel high on-treatment platelet reactivity (HTPR) in patients (n=112) with carotid artery stenosis undergoing endarterectomy (CEA). Methods: Using multiple-electrode impedance aggregometry (MEA) the antiplatelet effectiveness of clopidogrel was measured after 24 h, 7 and 30 days of clopidogrel treatment, which was introduced after elective CEA at a dose of 75 mg daily, for at least 30 days. Results: HTPR was observed among 25% patients after clopidogrel therapy for 30 days. Further analysis showed that 53.3% of patients carrying the CYP2C19*2 gene variant had clopidogrel-HTPR, while in the wild type group there were 14.6% (p lt 0.001). Multivariate logistic regression analysis identified the CYP2C19*2 variant allele (OR 4.384; 95% CI 1.296-14.833, p=0.017) and high total cholesterol level (OR 2.090; 95% CI 1.263-3.459, p=0.004) as the only independent risk factors for clopidogrel-HTPR. Conclusion: The CYP2C19*2 gene variant and high total cholesterol level were major factors for clopidogrel-HTPR in patients with carotid artery stenosis undergoing CEA.",
publisher = "Bentham Science Publ Ltd, Sharjah",
journal = "Current Vascular Pharmacology",
title = "Clopidogrel High On-Treatment Platelet Reactivity in Patients with Carotid Artery Stenosis Undergoing Endarterectomy. A Pilot Study",
pages = "569-563",
number = "6",
volume = "14",
doi = "10.2174/1570161114666160714103148"
}

Backović, D., Ignjatović, S., Rakićević, L., Novković, M., Kušić-Tišma, J., Radojković, D., Strugarević, E., Calija, B., Radak, D.,& Kovač, M.. (2016). Clopidogrel High On-Treatment Platelet Reactivity in Patients with Carotid Artery Stenosis Undergoing Endarterectomy. A Pilot Study. in Current Vascular Pharmacology
Bentham Science Publ Ltd, Sharjah., 14(6), 563-569.
https://doi.org/10.2174/1570161114666160714103148

Backović D, Ignjatović S, Rakićević L, Novković M, Kušić-Tišma J, Radojković D, Strugarević E, Calija B, Radak D, Kovač M. Clopidogrel High On-Treatment Platelet Reactivity in Patients with Carotid Artery Stenosis Undergoing Endarterectomy. A Pilot Study. in Current Vascular Pharmacology. 2016;14(6):563-569.
doi:10.2174/1570161114666160714103148 .

Backović, Dragana, Ignjatović, Svetlana, Rakićević, Ljiljana, Novković, Mirjana, Kušić-Tišma, Jelena, Radojković, Dragica, Strugarević, Evgenija, Calija, Branko, Radak, Djordje, Kovač, Mirjana, "Clopidogrel High On-Treatment Platelet Reactivity in Patients with Carotid Artery Stenosis Undergoing Endarterectomy. A Pilot Study" in Current Vascular Pharmacology, 14, no. 6 (2016):563-569,
https://doi.org/10.2174/1570161114666160714103148 . .

TY  - CONF
AU  - Backović, D.
AU  - Ignjatović, S.
AU  - Rakićević, Ljiljana
AU  - Novković, Mirjana
AU  - Kušić-Tišma, Jelena
AU  - Radojković, Dragica
AU  - Strugarević, E.
AU  - Calija, B.
AU  - Radak, D.
AU  - Kovač, Mirjana
PY  - 2016
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/940
PB  - Wiley-Blackwell, Hoboken
C3  - Journal of Thrombosis and Haemostasis
T1  - Risk factors for clopidogrel high on-treatment platelet reactivity in patients with carotid artery stenosis undergoing endarterectomy
EP  - 110
SP  - 110
VL  - 14
UR  - https://hdl.handle.net/21.15107/rcub_imagine_940
ER  - 

@conference{
author = "Backović, D. and Ignjatović, S. and Rakićević, Ljiljana and Novković, Mirjana and Kušić-Tišma, Jelena and Radojković, Dragica and Strugarević, E. and Calija, B. and Radak, D. and Kovač, Mirjana",
year = "2016",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Journal of Thrombosis and Haemostasis",
title = "Risk factors for clopidogrel high on-treatment platelet reactivity in patients with carotid artery stenosis undergoing endarterectomy",
pages = "110-110",
volume = "14",
url = "https://hdl.handle.net/21.15107/rcub_imagine_940"
}

Backović, D., Ignjatović, S., Rakićević, L., Novković, M., Kušić-Tišma, J., Radojković, D., Strugarević, E., Calija, B., Radak, D.,& Kovač, M.. (2016). Risk factors for clopidogrel high on-treatment platelet reactivity in patients with carotid artery stenosis undergoing endarterectomy. in Journal of Thrombosis and Haemostasis
Wiley-Blackwell, Hoboken., 14, 110-110.
https://hdl.handle.net/21.15107/rcub_imagine_940

Backović D, Ignjatović S, Rakićević L, Novković M, Kušić-Tišma J, Radojković D, Strugarević E, Calija B, Radak D, Kovač M. Risk factors for clopidogrel high on-treatment platelet reactivity in patients with carotid artery stenosis undergoing endarterectomy. in Journal of Thrombosis and Haemostasis. 2016;14:110-110.
https://hdl.handle.net/21.15107/rcub_imagine_940 .

Backović, D., Ignjatović, S., Rakićević, Ljiljana, Novković, Mirjana, Kušić-Tišma, Jelena, Radojković, Dragica, Strugarević, E., Calija, B., Radak, D., Kovač, Mirjana, "Risk factors for clopidogrel high on-treatment platelet reactivity in patients with carotid artery stenosis undergoing endarterectomy" in Journal of Thrombosis and Haemostasis, 14 (2016):110-110,
https://hdl.handle.net/21.15107/rcub_imagine_940 .